Eli Lilly acquires promising PI3Kα inhibitor from Scorpion Therapeutics
Eli Lilly and Company (Lilly) has announced a significant acquisition of Scorpion Therapeutics' mutant-selective PI3Kα inhibitor program, a move poised to enhance its oncology portfolio. ... Read More
Eli Lilly achieves breakthrough with Imlunestrant in Phase 3 breast cancer trial
Eli Lilly and Company has announced encouraging results from its Phase 3 EMBER-3 study evaluating imlunestrant, an investigational oral selective estrogen receptor degrader (SERD), for ... Read More
Lilly commits $3bn to Wisconsin facility to boost injectable medicine production
Eli Lilly and Company (Lilly) has unveiled plans for a $3 billion expansion of its newly acquired manufacturing facility in Kenosha County, Wisconsin, signalling a ... Read More
Lilly’s Phase 3 EMBER-3 trial results set to shake up breast cancer treatment landscape
Eli Lilly and Company (NYSE: LLY) announced it will present data from its Phase 3 EMBER-3 trial for imlunestrant, an oral selective estrogen receptor degrader ... Read More
Lilly launches $4.5bn medicine foundry to reshape drug production and clinical trials
Eli Lilly and Company has committed $4.5 billion to establish a revolutionary facility in Lebanon, Indiana—the Lilly Medicine Foundry. This one-of-a-kind site is set to ... Read More
Eli Lilly’s once-weekly insulin efsitora alfa matches daily insulin for A1C reduction, boosts stock interest
Eli Lilly and Company (NYSE: LLY) announced results from its QWINT-5 phase 3 trial, demonstrating that its once-weekly insulin efsitora alfa offers a comparable reduction ... Read More
Organon and Eli Lilly expand global reach of migraine treatment Emgality
Organon and Eli Lilly and Company have expanded their commercialization agreement for Emgality, a leading migraine treatment, into 11 additional markets, reinforcing their commitment to ... Read More
This diabetes breakthrough drug slashes risk by 94%—discover how tirzepatide is transforming obesity treatment
Eli Lilly and Company (NYSE: LLY) has released compelling results from the SURMOUNT-1 study, which highlights that tirzepatide (branded as Zepbound and Mounjaro) dramatically cuts ... Read More
Eli Lilly and OpenAI forge pioneering alliance to combat antimicrobial resistance
Eli Lilly and Company (NYSE: LLY) has entered into a partnership with OpenAI to harness generative AI for the discovery of new antimicrobials, aiming to ... Read More
Lilly to expand Indiana facility with record $5.3bn investment to boost production of APIs
In a historic move for the pharmaceutical industry, Eli Lilly and Company (NYSE: LLY) has announced a staggering $5.3 billion expansion of its Lebanon, Indiana ... Read More